A comprehensive view of DICE Therapeutics Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Eli Lilly completes acquisition of DICE Therapeutics, expanding its immunology portfolio with new oral therapeutic candidates
Published: August 10, 2023 by PharmaBiz (India)
Eli Lilly extends US$2.4B tender offer for Dice Therapeutics acquisition to August 8; Lilly also announces agreement to buy clinical-stage biopharmaceutical firm Versanis Bio for US$1.92B
Published: July 26, 2023 by MarketLine
Eli Lilly to acquire biopharma DICE Therapeutics for US$2.4B; DICE 's DELSCAPE technology platform develops novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology
Published: June 20, 2023 by Eli Lilly & Co.

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count